Last reviewed · How we verify
anti-TRBV9 monoclonal antibody infusions
anti-TRBV9 monoclonal antibody infusions is a monoclonal antibody (T-cell depleting) Biologic drug developed by Biocad. It is currently in Phase 3 development for T-cell lymphomas expressing TRBV9, Autoimmune diseases with TRBV9-positive T-cell involvement. Also known as: BCD-180 infusions.
This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions.
This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions. Used for T-cell lymphomas expressing TRBV9, Autoimmune diseases with TRBV9-positive T-cell involvement.
At a glance
| Generic name | anti-TRBV9 monoclonal antibody infusions |
|---|---|
| Also known as | BCD-180 infusions |
| Sponsor | Biocad |
| Drug class | monoclonal antibody (T-cell depleting) |
| Target | TRBV9 (T-cell receptor beta variable 9 segment) |
| Modality | Biologic |
| Therapeutic area | Immunology / Oncology |
| Phase | Phase 3 |
Mechanism of action
TRBV9 is a specific segment of the T-cell receptor beta chain expressed on a subset of T lymphocytes. By binding to TRBV9, this antibody marks these T cells for destruction via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This approach selectively targets potentially pathogenic T-cell clones while preserving much of the broader immune repertoire.
Approved indications
- T-cell lymphomas expressing TRBV9
- Autoimmune diseases with TRBV9-positive T-cell involvement
Common side effects
- Infusion-related reactions
- Lymphopenia
- Infections
- Cytokine release syndrome
Key clinical trials
- Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) (PHASE3)
- Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers (PHASE1)
- Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-TRBV9 monoclonal antibody infusions CI brief — competitive landscape report
- anti-TRBV9 monoclonal antibody infusions updates RSS · CI watch RSS
- Biocad portfolio CI
Frequently asked questions about anti-TRBV9 monoclonal antibody infusions
What is anti-TRBV9 monoclonal antibody infusions?
How does anti-TRBV9 monoclonal antibody infusions work?
What is anti-TRBV9 monoclonal antibody infusions used for?
Who makes anti-TRBV9 monoclonal antibody infusions?
Is anti-TRBV9 monoclonal antibody infusions also known as anything else?
What drug class is anti-TRBV9 monoclonal antibody infusions in?
What development phase is anti-TRBV9 monoclonal antibody infusions in?
What are the side effects of anti-TRBV9 monoclonal antibody infusions?
What does anti-TRBV9 monoclonal antibody infusions target?
Related
- Drug class: All monoclonal antibody (T-cell depleting) drugs
- Target: All drugs targeting TRBV9 (T-cell receptor beta variable 9 segment)
- Manufacturer: Biocad — full pipeline
- Therapeutic area: All drugs in Immunology / Oncology
- Indication: Drugs for T-cell lymphomas expressing TRBV9
- Indication: Drugs for Autoimmune diseases with TRBV9-positive T-cell involvement
- Also known as: BCD-180 infusions
- Compare: anti-TRBV9 monoclonal antibody infusions vs similar drugs
- Pricing: anti-TRBV9 monoclonal antibody infusions cost, discount & access